Effect of hepatic CYP inhibitors on the metabolism of sildenafil and formation of its metabolite, N-desmethylsildenafil, in rats in vitro and in vivo

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 12, 2009, Pages 1637-1642

  Baea, Soo H ^a   Baeb, Soo K ^b   Leea, Myung G ^a  

^a Seoul National University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

CYP inhibitors; Hepatic CYP2C11 and 3A1 2; N desmethylsildenafil; Pharmacokinetics; Rats; Sildenafil

Indexed keywords

CIMETIDINE; CYTOCHROME P450 2C11; CYTOCHROME P450 2C9; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; NORSILDENAFIL; QUININE; SILDENAFIL; SULFAPHENAZOLE; TROLEANDOMYCIN; UDENAFIL; UK 103320; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME KINETICS; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; LIVER; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TROLEANDOMYCIN;

EID: 75749154470     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.12.0008     Document Type: Article

References (34)

1. Shin HS et al. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm 2006; 320: 64-70.
2. Walker DK et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
3. Merry C et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999; 13: F101-F107.
4. Muirhead GJ et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
5. Jetter A et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002; 71: 21-29.
6. Muirhead GJ et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002; 53(Suppl. 1): 37S-43S.
7. Wilner K et al. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol 2002; 53(Suppl. 1): 31S-36S.
8. Hesse C et al. Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 2005; 25: 589-592.
9. Hedaya MA et al. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharm Drug Dispos 2006; 27: 103-110.
10. Warrington JS et al. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 1999; 28: 392-397.
11. Hyland R et al. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51: 239-248.
12. Warrington JS et al. In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. Drug Metab Dispos 2002; 30: 655-657.
13. Shim HJ et al. Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. Biopharm Drug Dispos 2005; 26: 161-166.
14. Elsherbiny ME et al. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 2008; 11: 147-159.
15. Lewis DFV. P450 substrate, specificity and metabolism. In: Cytochrome P450. Structure, Function and Metabolism. Bristol, PA: Taylor & Francis, 1996: 123.
16. Sinclair J et al. Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin. Biochem Pharmacol 2000; 59: 227-232.
17. Kobayashi K et al. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 2003; 31: 833-836.
18. Kobayashi S et al. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989; 38: 2795-2799.
19. Ogiso T et al. Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Biol Pharm Bull 1999; 22: 196-199.
20. Tomkins DM et al. Effects of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 1997; 280: 1374-1382.
21. Levine M et al. In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther 1998; 284: 493-499.
22. Oh EY et al. Pharmacokinetic and pharmacodynamic consequences of inhibition of terazocin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. Br J Pharmacol 2007; 151: 24-34.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
24. Huskey SW et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 1995; 31: 833-836.
25. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.
26. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level - time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
27. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, 1982.
28. Kim SH et al. Pharmacokinetics and pharmacodynamics of furosemide in protein - calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
29. Chang T et al. Selective inhibition of rat hepatic microsomal cytochrome P-450. II. Effect of the in vitro administration of cimetidine. J Pharmacol Exp Ther 1992; 260: 1450-1455.
30. Cho MK et al. Suppression of rat hepatic cytochrome P450s by protein - calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 1999; 372: 150-158.
31. Moon YJ et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
32. Kim YC et al. Pharmacokinetics of theophylline in diabetes mellitus rat: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 2005; 26: 114-123.
33. Yang KH, Lee MG. Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs. Arch Pharm Res 2008; 31: 1073-1086.
34. Yang KH, Lee MG. Effects of lipopolysaccharide on pharmacokinetics of drugs. Toxicol Res 2007; 23: 289-299.